Back |
home / stock / iugnf / iugnf message board
Subject | By | Source | When |
---|---|---|---|
Been away for a while moving. I have | Maka67 | investorshub | 01/14/2020 4:32:22 AM |
Quite a few outstanding shares. Seems like an | WhinePress | investorshub | 12/05/2019 1:47:53 AM |
CF33 Oncolytic Virus GMP Manufacturing Update | Bottom Fisher | investorshub | 11/26/2019 2:30:47 PM |
$IUGNF: If MERCK is involved with IMUGENE | makinezmoney | investorshub | 11/21/2019 2:56:31 PM |
I have a feeling this stock hits scanners | Bottom Fisher | investorshub | 11/21/2019 2:54:14 PM |
$IUGNF: WOW... I was just reading this in | makinezmoney | investorshub | 11/21/2019 2:03:14 PM |
Imugene Limited(ASX: IMU) ONCOLYTIC VIRUS ACQUISITION COMPLETE | Bottom Fisher | investorshub | 11/21/2019 1:16:24 PM |
no. the AS is determined. thr flost is | Dick Goblair | investorshub | 11/21/2019 4:14:01 AM |
MMs still have to get their shares. They | Bottom Fisher | investorshub | 11/21/2019 4:11:21 AM |
that is not true at all they absolutely do | Dick Goblair | investorshub | 11/21/2019 2:54:25 AM |
Well, it is not like the MMs just | Bottom Fisher | investorshub | 11/21/2019 2:50:41 AM |
Short video | soseano | investorshub | 11/21/2019 1:07:40 AM |
News, Short Squeeze, Breakout and More Instantly...
Imugene Ltd Company Name:
IUGNF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss the strategic partnership the company has formed with Kincell Bio, LLC that involves the sale of Imugene's Current Good Manufacturing Practice (CGMP) complia...
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieve...
(NewsDirect) Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss enrolment for a pivotal expansion study targeting bile tract cancer (cholangiocarcinoma) patients. This follows the successful completion of the fifth high-dose cohort in the intr...